Tenax Therapeutics vs Tvardi Therapeutics
TENX and TVRD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How TENX and TVRD compare
Tenax Therapeutics is the larger company, worth 3.9 times as much as Tvardi Therapeutics ($60.6M against $15.7M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | TENX | TVRD |
|---|---|---|
| Size and price | ||
| Market cap | $60.6M | $15.7M |
| Share price | $1.62 | $1.18 |
| Change, 1 year | −76.8% | −72.2% |
| Change, 5 years | −99.9% | −99.8% |
| Beta (5Y) | 0.62 | 1.11 |
| Employees | 14 | 12 |
| StockData Score | ||
| Total score | 6 | 6 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.6× (better) | 1.0× |
| Profitability | ||
| Return on equity | −64.2% (better) | −123% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 14.01 (better) | 2.86 |
| Altman Z-score | −1.49 (better) | −9.66 |
| Piotroski F-score | 2 (better) | 1 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 81.1% | 16.7% |
| Held by insiders | 4.8% | 15.6% |
| Insider net buying, 12 months | $6.5M | – |
| Short interest, % of float | 16.3% | 2.7% |
Go deeper
- TENX stock overview
- TENX income statement
- TENX valuation and score
- TVRD stock overview
- TVRD income statement
- TVRD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.